Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women?

Metabolism: Clinical and Experimental
Martin BrochuE T Poehlman

Abstract

It is presently unclear how much visceral adipose tissue (VAT) loss is needed to induce favorable metabolic changes. Cross-sectional studies have proposed that a threshold level of VAT exceeding 110 cm(2) in women induces deleterious changes in the metabolic profile. It is presently unclear, however, if significant decreases in VAT below this given threshold significantly improve the metabolic profile more as compared to decreases that remain below 110 cm(2). To examine whether achieving versus not achieving the proposed VAT threshold impacts differently on the metabolic profile in postmenopausal women, we examined the effects of a VAT loss below the 110-cm(2) threshold versus those individuals who remained higher than 110 cm(2) after a weight loss program. Twenty-five sedentary obese (baseline % body fat, 47.7% +/- 4.1%; [mean +/- SD]) postmenopausal women aged between 51 and 71 years (59.7 +/- 5.6 years) and displaying high baseline levels of VAT accumulation (223 +/- 45 cm(2)) were submitted to a 1-year weight loss program with weight stabilization periods before and after weight reduction. Based on their loss of VAT after weight loss, subjects were characterized as "attainers" (post VAT levels < 110 cm(2); average, 96 +/- 1...Continue Reading

Citations

May 21, 2010·European Journal of Clinical Nutrition·F HosseinpanahF Azizi
Jun 24, 2011·European Journal of Clinical Nutrition·E L ThomasJ D Beaver
Jan 4, 2007·Diabetes, Obesity & Metabolism·Neda RasouliPhilip A Kern
Mar 19, 2008·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Hélène ArguinMartin Brochu
Dec 19, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·C E Hallgreen, K D Hall
Dec 17, 2008·Diabetes Care·Karla M PouCaroline S Fox
Oct 23, 2009·Metabolism: Clinical and Experimental·Martin SénéchalMartin Brochu
Mar 8, 2014·Scandinavian Journal of Medicine & Science in Sports·J A L CalbetH-C Holmberg
Apr 12, 2017·Menopause : the Journal of the North American Menopause Society·Ahmed GhachemMartin Brochu
Jun 16, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A OnatV Sansoy
Mar 14, 2018·Menopause : the Journal of the North American Menopause Society·Chao-Chun ChengJen-Fang Liu
Feb 17, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Giamila Fantuzzi, Theodore Mazzone
Oct 27, 2009·American Journal of Human Biology : the Official Journal of the Human Biology Council·Julienne N RutherfordChristopherw Kuzawa
Mar 15, 2006·Medicine and Science in Sports and Exercise·Manish MohankaAnne McTiernan
May 17, 2007·The Journal of Clinical Endocrinology and Metabolism·Lisa J MoranRobert J Norman
Jun 9, 2015·The Journal of Clinical Hypertension·Abiodun M AdeoyeBamidele O Tayo
Sep 11, 2018·Periodontology 2000·Jean E SuvanFrancesco D'Aiuto
Oct 21, 2020·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·René MaréchalMartin Brochu
May 15, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Jenna L TaylorShelley E Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.